A citation-based method for searching scientific literature

Nicholas P Giustini, Lyudmila Bazhenova. Thorac Surg Clin 2020
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
247
33

Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye-Jeong Lee, Jin Hur, Byoung Wook Choi. Thorac Cancer 2020
29
33

Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients.
Lan Song, Zhenchen Zhu, Li Mao, Xiuli Li, Wei Han, Huayang Du, Huanwen Wu, Wei Song, Zhengyu Jin. Front Oncol 2020
25
33

Targeted Therapy for Mutation-Driven Metastatic Non-Small-Cell Lung Cancer: Considerations for ALK-Rearranged Tumors.
Kathryn F Mileham, Mufti N Ahmad, Edward S Kim. Oncology (Williston Park) 2019
1
100

Radiomics and radiogenomics of prostate cancer.
Clayton P Smith, Marcin Czarniecki, Sherif Mehralivand, Radka Stoyanova, Peter L Choyke, Stephanie Harmon, Baris Turkbey. Abdom Radiol (NY) 2019
28
33

Overview of radiomics in breast cancer diagnosis and prognostication.
Alberto Stefano Tagliafico, Michele Piana, Daniela Schenone, Rita Lai, Anna Maria Massone, Nehmat Houssami. Breast 2020
67
33

Predictive radiogenomics modeling of EGFR mutation status in lung cancer.
Olivier Gevaert, Sebastian Echegaray, Amanda Khuong, Chuong D Hoang, Joseph B Shrager, Kirstin C Jensen, Gerald J Berry, H Henry Guo, Charles Lau, Sylvia K Plevritis,[...]. Sci Rep 2017
87
33

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Weijing Cai, Dongmei Lin, Chunyan Wu, Xuefei Li, Chao Zhao, Limou Zheng, Shannon Chuai, Ke Fei, Caicun Zhou, Fred R Hirsch. J Clin Oncol 2015
104
33

Radiomics on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for Prediction of Postoperative Early and Late Recurrence of Single Hepatocellular Carcinoma.
Sungwon Kim, Jaeseung Shin, Do-Young Kim, Gi Hong Choi, Myeong-Jin Kim, Jin-Young Choi. Clin Cancer Res 2019
80
33

Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.
Ying Liu, Jongphil Kim, Yoganand Balagurunathan, Qian Li, Alberto L Garcia, Olya Stringfield, Zhaoxiang Ye, Robert J Gillies. Clin Lung Cancer 2016
165
33

Validation of A Method to Compensate Multicenter Effects Affecting CT Radiomics.
Fanny Orlhac, Frédérique Frouin, Christophe Nioche, Nicholas Ayache, Irène Buvat. Radiology 2019
152
33

Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
Fang Hu, Changhui Li, Jianlin Xu, Jindong Guo, Yinchen Shen, Wei Nie, Xiaoxuan Zheng, Lixin Wang, Hai Zhang, Baohui Han,[...]. Lung Cancer 2019
9
33

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rafael Rosell, Niki Karachaliou, Juergen Wolf, Sai-Hong Ignatius Ou. Lancet Respir Med 2014
12
33

TRK Inhibitors in Non-Small Cell Lung Cancer.
Guilherme Harada, Aline Bobato Lara Gongora, Cesar Martins da Costa, Fernando Costa Santini. Curr Treat Options Oncol 2020
7
33

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.
Igor Letovanec, Stephen Finn, Panagiota Zygoura, Paul Smyth, Alex Soltermann, Lukas Bubendorf, Ernst-Jan Speel, Antonio Marchetti, Daisuke Nonaka, Kim Monkhorst,[...]. J Thorac Oncol 2018
55
33

Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.
Maomei Ruan, Liu Liu, Lihua Wang, Bei Lei, Xiaoyan Sun, Cheng Chang, Yan Shen, Wenhui Xie. Eur J Nucl Med Mol Imaging 2020
6
33

Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
Jason N Rosenbaum, Ryan Bloom, Jason T Forys, Jeff Hiken, Jon R Armstrong, Julie Branson, Samantha McNulty, Priya D Velu, Kymberlie Pepin, Haley Abel,[...]. Mod Pathol 2018
46
33


SUVmax of 18FDG PET/CT Predicts Histological Grade of Lung Adenocarcinoma.
Xiao-Yan Sun, Tian-Xiang Chen, Cheng Chang, Hao-Hua Teng, Chun Xie, Mao-Mei Ruan, Bei Lei, Liu Liu, Li-Hua Wang, Yun-Hai Yang,[...]. Acad Radiol 2021
8
33

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Hyojin Kim, Seol-Bong Yoo, Ji-Young Choe, Jin Ho Paik, Xianhua Xu, Hiroaki Nitta, Wenjun Zhang, Thomas M Grogan, Choon-Taek Lee, Sanghoon Jheon,[...]. J Thorac Oncol 2011
126
33

Minor components of micropapillary and solid subtypes in lung invasive adenocarcinoma (≤ 3 cm): PET/CT findings and correlations with lymph node metastasis.
Cheng Chang, Xiaoyan Sun, Wenlu Zhao, Rui Wang, Xiaohua Qian, Bei Lei, Lihua Wang, Liu Liu, Maomei Ruan, Wenhui Xie,[...]. Radiol Med 2020
16
33

Radiomics based likelihood functions for cancer diagnosis.
Hina Shakir, Yiming Deng, Haroon Rasheed, Tariq Mairaj Rasool Khan. Sci Rep 2019
12
33

Targeting BRAF mutations in non-small cell lung cancer.
Connor Gerard O'Leary, Vladamir Andelkovic, Rahul Ladwa, Nick Pavlakis, Caicun Zhou, Fred Hirsch, Derek Richard, Kenneth O'Byrne. Transl Lung Cancer Res 2019
30
33

ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Xue Du, Yun Shao, Hai-Feng Qin, Yan-Hong Tai, Hong-Jun Gao. Thorac Cancer 2018
91
33

Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
Ka-Fai To, Joanna H M Tong, King S F Yeung, Raymond W M Lung, Peggy P Y Law, Shuk Ling Chau, Wei Kang, Carol Y K Tong, Chit Chow, Anthony W H Chan,[...]. J Thorac Oncol 2013
57
33

Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer.
Chintan Parmar, Patrick Grossmann, Derek Rietveld, Michelle M Rietbergen, Philippe Lambin, Hugo J W L Aerts. Front Oncol 2015
218
33

Radiomics and radiogenomics in lung cancer: A review for the clinician.
Rajat Thawani, Michael McLane, Niha Beig, Soumya Ghose, Prateek Prasanna, Vamsidhar Velcheti, Anant Madabhushi. Lung Cancer 2018
219
33

CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma.
Tong-Xu Shen, Lin Liu, Wen-Hui Li, Ping Fu, Kai Xu, Yu-Qing Jiang, Feng Pan, Yan Guo, Meng-Chao Zhang. Cancer Imaging 2019
18
33

Radiomics for classification of bone mineral loss: A machine learning study.
S Rastegar, M Vaziri, Y Qasempour, M R Akhash, N Abdalvand, I Shiri, H Abdollahi, H Zaidi. Diagn Interv Imaging 2020
34
33

CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study.
Hailin Li, Rui Zhang, Siwen Wang, Mengjie Fang, Yongbei Zhu, Zhenhua Hu, Di Dong, Jingyun Shi, Jie Tian. Front Oncol 2020
19
33

Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
Yi-Cheng Wu, Il-Chi Chang, Chi-Liang Wang, Tai-Di Chen, Ya-Ting Chen, Hui-Ping Liu, Yen Chu, Yu-Ting Chiu, Tzu-Hua Wu, Li-Hui Chou,[...]. PLoS One 2013
85
33

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.
Federica Zito Marino, Giuseppina Liguori, Gabriella Aquino, Elvira La Mantia, Silvano Bosari, Stefano Ferrero, Lorenzo Rosso, Gabriella Gaudioso, Nicla De Rosa, Marianna Scrima,[...]. PLoS One 2015
17
33

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Narjust Duma, Rafael Santana-Davila, Julian R Molina. Mayo Clin Proc 2019
555
33

A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling.
Stefan Leger, Alex Zwanenburg, Karoline Pilz, Fabian Lohaus, Annett Linge, Klaus Zöphel, Jörg Kotzerke, Andreas Schreiber, Inge Tinhofer, Volker Budach,[...]. Sci Rep 2017
106
33

Estimation of the Youden Index and its associated cutoff point.
Ronen Fluss, David Faraggi, Benjamin Reiser. Biom J 2005
33

Epidermal Growth Factor Receptor Mutations.
Erin M McLoughlin, Ryan D Gentzler. Thorac Surg Clin 2020
9
33

MRI radiomics analysis for predicting preoperative synchronous distant metastasis in patients with rectal cancer.
Huanhuan Liu, Caiyuan Zhang, Lijun Wang, Ran Luo, Jinning Li, Hui Zheng, Qiufeng Yin, Zhongyang Zhang, Shaofeng Duan, Xin Li,[...]. Eur Radiol 2019
48
33

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells. PLoS One 2020
30
33

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
Anthony V Serritella, Christine M Bestvina. Thorac Surg Clin 2020
5
33


The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
33

Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Isaac Shiri, Hasan Maleki, Ghasem Hajianfar, Hamid Abdollahi, Saeed Ashrafinia, Mathieu Hatt, Habib Zaidi, Mehrdad Oveisi, Arman Rahmim. Mol Imaging Biol 2020
56
33

ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
Shota Yamamoto, Ronald L Korn, Rahmi Oklu, Christopher Migdal, Michael B Gotway, Glen J Weiss, A John Iafrate, Dong-Wan Kim, Michael D Kuo. Radiology 2014
103
33

FGF/FGFR signaling pathway involved resistance in various cancer types.
Yangyang Zhou, Chengyu Wu, Guangrong Lu, Zijing Hu, Qiuxiang Chen, Xiaojing Du. J Cancer 2020
33
33

Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.
Tahira Khan, Mark Stewart, Samuel Blackman, Raphaël Rousseau, Martha Donoghue, Kenneth Cohen, Nita Seibel, Mark Fleury, Bouchra Benettaib, Raleigh Malik,[...]. Ther Innov Regul Sci 2019
16
33

Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies.
R Tyler Hillman, Kristy Ward, Cheryl Saenz, Michael McHale, Steven Plaxe. J Pers Med 2015
6
33

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan. Ann Oncol 2017
33

RET fusions in solid tumors.
Andrew Y Li, Michael G McCusker, Alessandro Russo, Katherine A Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo. Cancer Treat Rev 2019
81
33

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob,[...]. Lancet 2015
857
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.